Izvorni znanstveni članak
https://doi.org/10.3325/cmj.2020.61.450
Kallikrein gene family as biomarkers for recurrent prostate cancer
Fatma Busra Boyukozer
; Department of Molecular and Medical Genetics, Biruni University, Istanbul, Turkey
Esra Guzel Tanoglu
; Department of Molecular Biology and Genetics, University of Health Sciences, Istanbul, Turkey
Mustafa Ozen
; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX
Michael Ittmann
; Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX
Elif Sibel Aslan
; Department of Molecular Biology and Genetics, Biruni University, Istanbul, Turkey
Sažetak
Aim To assess kallikrein (KLK) expression in recurrent and
non-recurrent prostate tumors and adjacent healthy prostate tissues.
Methods The expression levels of 15 KLK genes in 34 recurrent and 36 non-recurrent prostate cancer samples and
19 adjacent healthy prostate tissue samples was assessed
with quantitative reverse-transcription polymerase chain
reaction. The samples were obtained from Baylor College
of Medicine, Houston, TX, USA between 2013 and 2016 .
Results Compared with controls, prostate cancer samples
showed a strong decrease in KLK1, KLK4, KLK9, and KLK14.
Recurrent samples were negative for KLK1, KLK2, and KLK14
but demonstrated higher levels of KLK3, KLK4, and KLK9
than controls. Other KLKs were not significantly expressed.
Conclusion This study for the first time showed a difference in the expression levels of the KLK gene family in recurrent prostate cancer. KLKs could be used as recurrence
markers for prostate cancer.
Ključne riječi
Hrčak ID:
277995
URI
Datum izdavanja:
23.10.2020.
Posjeta: 780 *